Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 107

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 107
---
premium pricing typical of targeted liposomal oncology therapeutics, the severity of pancreatic cancer, U.S. payer willingness to reimburse
high-cost treatments, and the lack of effective alternatives.

At assumed ~20% market penetration, projected
global revenue could reach $632 million to 1.26 billion annually. This reflects the premium pricing typical of targeted liposomal oncology
therapeutics, but also accounts for lower payer ability to reimburse outside the U.S. and greater variability in adoption and uptake
across geographies.

Estimated Market Opportunity Summary for Nano-Candesartan (Liposomal ARB) in Pancreatic Cancer

| Geography |     | Estimated               
 Annual Cases            |     | Assumed Pricing (per patient)                     |     | TAM (100%    
 Coverage)    |     | SOM (Realistic      
 Penetration)        |
| U.S.      |     | ~61,000 new PDAC cases  |     | ~$12,950–$25,900 (3.5 months PPPM: $3,700–$7,400) |     | ~$0.8B–$1.6B |     | ~$390M–$790M        
 at ~50% penetration |
| Global    |     | ~495,000 new PDAC cases |     | ~$12,950–$25,900 (same per-patient assumption)    |     | ~$3.2B–$6.3B |     | ~$0.6B–$1.3B        
 at ~20% penetration |

The assumed pricing profile is based on benchmarks from other liposomal oncology drugs. While its potential use in a high-mortality, high-cost indication supports commercial attractiveness and significant global revenue potential, these estimates reflect our assumptions that are illustrative only. Actual outcomes will depend on future clinical trial results, regulatory approvals, regimen.

Our product candidate is still in preclinical
development and has not been approved by any regulatory authority. We do not yet know the final dosage, or number of injections required
per treatment course, and actual pricing will depend on multiple factors including clinical results, regulatory approval, reimbursement,
adoption, and competition.

<div align='center'>69</div>

References

| 1. | American Cancer Society. Pancreatic Cancer Survival Rates. https://www.cancer.org |

| 2. | GoodRx (2024). Gemzar and Abraxane Pricing Estimates. https://www.goodrx.com